Eukaryotic pre-mRNA splicing is regulated by consensus sequences at the intron boundaries and branch site. Recently, Sirand-Pugnet et al. reported the importance of an additional intronic sequence, an (A/U)GGG repeat in chicken β-tropomyosin that is a binding site for a protein required for spliceosome assembly. Interestingly, we have detected mutations in IVS3 of the human growth hormone (GH) gene that affect a putative, homologous consensus sequence and which also perturb splicing. In a series of dominant-negative GH mutations that cause exon skipping, we found two mutations that do not occur within the 5′ and 3′ splice sites, or branch consensus sites. The first mutation is a G!A transition of the 28th base (+28G!A) of and the second deletes 18 bp (del+28-45) of IVS3 of the human GH gene. These mutations segregated with autosomal dominant GH deficiency in both kindreds and no other allelic GH gene changes were detected. RT-PCR amplification of transcripts from expression vectors containing the +28G!A or del+28-45 alleles yielded products showing a >10-fold preferred use of alternative splicing, similar to findings previously reported for IVS3 donor site mutations. Both mutations are located 28 bp downstream from the 5′ splice site and examination of the sequences perturbed revealed an intronic XGGG repeat similar to the repeat found to regulate mRNA splicing in chicken β-tropomyosin. Interestingly, the XGGG repeats involved in our mutations exhibit homologous spacing to those in a so-called 'winner' RNA sequence. Binding of A1 heterogeneous nuclear ribonucleoprotein (hnRNP) by 'winner' sequences in pre-mRNA transcripts is thought to play an important role in pre-mRNA packaging and transport as well as 5′ splice site selection in pre-mRNAs that contain multiple 5′ splice sites. Our findings suggest that (i) XGGG repeats may regulate alternative splicing in the human GH gene and (ii) mutations of these repeats cause GH deficiency by perturbing alternative splicing. Mutations of homologous intron sequences may underlie other human diseases.
INTRODUCTION
Pre-mRNA processing to remove intervening sequences (introns) utilizes conserved sequences at the 5′ and 3′ splice sites, and branch consensus site of the introns (1) . However, these conserved sequences alone are not sufficient to explain the splicing process because the presence of cryptic splice sites, which are either not utilized or are preferentially involved in tissue specific alternative splicing, suggests that other cis-acting elements must exist (2, 3) .
Growth hormone (GH) gene defects that cause some cases of autosomal dominant isolated GH deficiency (IGHD II) have been previously reported (4) (5) (6) . These mutations have all occurred within the 5′ splice site of IVS3 resulting in aberrant splicing and deletion of exon 3. This exon 3 skipping deletes 120 nucleotides (nt) which correspond to amino acids 32-71 and results in a truncated GH protein that corresponds to the 17.5 kDa isoform of GH.
We report here two additional IGHD II IVS3 mutations, from two non-related kindreds, which also perturb splicing and cause exon 3 skipping, but do not occur within the IVS3 branch consensus, 5′ or 3′ splice sites. These mutations derange sequences homologous to XGGG repeats that regulate alternative mRNA splicing in the chicken β-tropomyosin gene and sequences that form G-quartets which bind the A1 heterogeneous nuclear ribonucleoprotein (hnRNP) (16) (17) .
RESULTS
To determine the segregation patterns of GH alleles, DNA from the members of two IGHD II families were genotyped for a dinucleotide repeat polymorphism within the GH gene cluster (8) . The results were consistent with transmission of an abnormal GH1 allele from the affected parent to each affected child and *To whom correspondence should be addressed. Tel: +1 615 322 7601; Fax: +1 615 343 9951; Email: john.phillips@mcmail.vanderbilt.edu Figure 1 . Comparison of DNA sequencing ladders of IGHD II patient 1 (left), patient 2 (right) and a normal control (center). DNA sequences of patient 1 and the normal control were derived from direct sequencing of PCR-amplified GH genes obtained using genomic DNA as templates. Patient 2's DNA sequence was derived from cycle sequencing of cloned PCR products.
co-segregation of this GH1 allele with the IGHD II phenotype (data not shown). Furthermore, the mutant alleles in the Thai family were in coupling with the same polymorphic dinucleotide repeat allele in all individuals genotyped.
The sequences of the GH1 alleles of an affected child from Family 1 were determined by direct sequencing of PCR products while those in the affected child from Family 2 were determined by sequencing the cloned PCR products (Fig. 1 ). Note that patient 1 (arrow) from Family 1 as well as both affected parents and sibs are heterozygous for a G!A transition of the 28th base of IVS3 (IVS3 +28G!A). Patient 2 (arrow) from Family 2, as well as his affected father and son, is heterozygous for an 18 bp deletion of bases 28-45 of IVS3 (IVS3 del+28-45) .
The G!A transition found in DNA from Family 1 destroyed a FokI site, which was used to confirm the mutation in DNA from all family members studied as well as to study DNA from 66 non-related controls (CEPH parents). Digestion of the 259 bp PCR products with FokI generated three fragments of 195, 43 and 21 bp in normal subjects. The presence of the IVS3 +28G!A transition destroys one of the FokI sites generating an additional 64 bp fragment (43 + 21 bp). All five affected members of Family 1 who were studied were found to have the 194, 64, 43 and 21 bp fragments indicating that all are heterozygous for the mutation (see Fig. 2a ). Analysis of DNA from 66 non-related controls did not detect any GH alleles that yielded an additional 64 bp fragment (data not shown).
The 18 bp IVS3 del+28-45 found in patient 2 was screened for in DNA from all family members by PCR amplification of the affected region which generates a 259 bp fragment for the normal allele and a 241 bp fragment for the mutant allele. Using this method, PCR products of the GH1 alleles of affected family members demonstrated that all were heterozygous for the IVS3 +28-45 deletion while all unaffected family members were found to be homozygous normal (see Fig. 2b ). In addition, this deletion was not found in any GH alleles from 66 non-related controls (CEPH parents) whose DNAs were studied (data not shown).
To determine the effects of the two mutations on GH mRNA splicing, expression plasmids containing the normal GH1 gene, the IVS3 +28G!A, the IVS3 del+28-45, or the previously reported IVS3 +1G!A IGHD II mutant alleles were transfected into HeLa cells, and the resulting GH transcripts were analyzed by DNA sequencing of RT-PCR products (4). The normal GH1 gene yielded normally spliced GH transcripts while the IVS3 +28G!A and del+28-45 mutants, like the previously reported IVS3 +1G!A mutant, exhibited aberrant splicing with skipping of exon 3. All three mutant alleles yielded mRNAs which had lost codons for amino acids 32-71 and whose translation products are predicted to correspond to the 17.5 kDa isoform of GH (Fig. 3 ) (14) . These transfections were repeated using GH3 cells (rat pituitary cells that synthesize GH) and gave the same results (data not shown) as those shown for HeLa cells in Figure 3 .
DISCUSSION
Sequence analysis of RT-PCR products from mRNA transcripts generated in transient expression studies of these two mutations in IVS3 of the human GH gene showed that both mutations caused aberrant splicing, with skipping of exon 3 as reported previously with IVS3 donor splice site mutations. Since neither IVS3 +28G!A nor del+28-45 are located within the 5′ and 3′ splice, or branch consensus sites, we concluded they must perturb a previously unidentified regulatory region (see Fig. 4 ).
Computer analysis of human intronic sequences, previously reported by Engelbrecht et al., has shown that the first 50 nt of introns are particularly GC-rich (15) . More specifically, GGG repeats were found to occur four times more frequently in introns than would be expected. Interestingly, Pugnet et al. reported an intronic (A/U)GGG repeat important for mRNA splicing of IVSB7 in chicken β-tropomyosin transcripts (16) . They found that the six (A/U)GGG repeats had an additive effect and were necessary for spliceosome assembly. Finally, using UV crosslinking experiments they identified a 55 kDa protein which bound to the region and was present in splicing complexes.
The region of IVS3 of the human GH gene perturbed by our mutations and shown to be important in splicing is also guanosine rich with a motif similar to that of chicken β-tropomyosin. By sequence analysis of the human GH gene, we found that XGGG sequences are about five times more common in GH introns than exons. Furthermore, when tandem XGGG repeats were sought, we found these in IVS1, -3 and -4. Interestingly, IVS3 is unique in having a single set of tandem XGGG repeats (CGGGG and TGGGG) in the absence of any additional, non-tandem repeats. The first of these tandem repeats is altered (XGGG!XGGA) by the +28G!A mutation and the second repeat is deleted by the del+28-45 mutation (see Fig. 4 ). Experiments to determine the relative contribution of each repeat to correct splicing of GH mRNA transcripts are underway.
Interestingly, the GGG repeats involved in our mutations exhibit homologous spacing to those in the so-called 'winner' RNA sequence (UAUGAUAGGGACUUAGGGUG) (17) . Two winner sequences are thought to aggregate in solution to form a G-quartet from dimerization of two Hoogsteen base-paired hairpins. Binding of A1 heterogeneous nuclear ribonucleoprotein (hnRNP) by these sequences in pre-mRNA transcripts is thought to play an important role in pre-mRNA packaging and transport, as well as 5′ splice site selection, in pre-mRNAs that contain multiple 5′ splice sites (17) . Our data suggest that XGGG repeats may regulate alternative splicing in the human GH gene. Perturbations of these sites cause GH deficiency through alternative splicing, suggesting that mutations of homologous intron sequences may underlie other human diseases.
MATERIALS AND METHODS

Subjects
We studied DNAs from two non-related kindreds. The patients were diagnosed as having familial IGHD II by the following criteria: multiple relatives were affected in an apparent autosomal dominant mode and probands had severe growth retardation, low basal and post stimulation GH levels, normal thyroid hormone levels, and positive responses to hGH replacement. Family 2 was originally described by Poskitt and Rayner in 1974 (7).
Segregation
DNAs were isolated from peripheral blood samples from all family members and controls. The samples were genotyped for a dinucleotide repeat polymorphism within the GH gene cluster as described by Polymeropoulos et al. with some modifications (8) . The forward and reverse primers corresponding to nt 25718-25736 (5′-ACTGCACTCCAGCCTCGGA-3′) and the complement of 26049-26031 (5′-ATGGCACTCCAGCCTGGGC-3′) of the GH gene cluster respectively (9) . The PCR reaction mixture was denatured for 5 min at 94_C, cycled 27 times (94_C, 30 s; 59_C, 30 s; 72_C, 30 s), followed by a 10 min extension at 72_C. The PCR products were separated on a 6% denaturing polyacrylamide gel and visualized by autoradiography.
PCR amplification of genomic DNA and DNA sequencing
The GH1 genes of an affected child from each family were PCR amplified using forward and reverse primers corresponding to nt 4556-4575 (5′-CCAGCAATGCTCAGGGAAAG-3′) and the complement of 7255-7226 (5′-TGTCCCACCGGTTGGGCATG-GCAGGTAGCC-3′) of the GH gene cluster, respectively (10) . The PCR reaction mixture was denatured for 6 min at 94_C, cycled 32 times (94_C, 1 min; 65_C, 45 s; 72_C, 3 min), followed by a 10 min extension at 72_C. The resulting GH1 PCR products (2700 bp) were cleaned by filtration with a Centricon 100 microconcentrator (Amicon Corp., Danvers, MA) and used as templates for a second PCR using forward and reverse primers corresponding to nt 4599-4615 (TTCTCTCTAGTGGT-CAGTGT) and the complement of 7206-7187 (CTCCTGCT-GGTATACTTATT) of the gene cluster, respectively (2). The PCR reaction mixture was denatured for 6 min at 94_C, cycled 32 times (94_C, 1 min; 54_C, 45 s; 72_C, 3 min), followed by a 10 min extension at 72_C. The resulting GH1 PCR products (2608 bp) were cleaned by filtration with a Centricon 100 microconcentrator (Amicon Corp., Danvers, MA) and then either sequenced directly (patient 1) or cloned into a pUC18 vector using the SureClone Ligation Kit (Pharmacia Biotech) (patient 2) and then sequenced by the dideoxy method (11) using the ThermoSequenase cycle sequencing system (Amersham Life Science, Cleveland, OH) (see Fig. 1 ).
PCR/restriction endonuclease detection of mutations
The 2608 bp GH1 PCR amplification products were used as templates for an internal PCR containing the mutated region under standard PCR conditions with forward and reverse primers corresponding to nt 5810-5833 (GTAACAATGGGAGCTGG-TCTCCAG) and the complement of 6068-6046 (GAAG-GACGGGCATTGGCTGTGCT) of the gene cluster, respectively (9) . PCR reaction mixtures were denatured for 6 min at 94_C, cycled 32 times (94_C, 45 s; 67_C, 45 s; 72_C, 1 min), followed by a 10 min extension at 72_C. For Family 1 aliquots were then digested with FokI and separated on a 5% Metaphor agarose gel and visualized by ethidium bromide staining. In Family 2, aliquots were analyzed directly by visualization in an ethidium bromide stained 3% Metaphor agarose gel.
Site directed mutagenesis and in vitro expression studies
Human GH expression vectors containing the IVS3 +28G!A and the del+28-45 mutations were constructed using the Muta-Gene T7 M13 In Vitro Mutagenesis Kit (BioRad Laboratories, Hercules, CA). The entire GH1 gene, with introns, was excised from the GH expression vector pXGH5 (Nichols Diagnostics Institute, San Juan Capistrano, CA) by digestion with EcoRI (New England Biolabs, Inc., Beverly, MA) and subcloned into the M13mp19 vector which had also been digested with EcoRI. Site directed mutagenesis (12,13) was carried out using an oligonucleotide containing the desired mutation (5′-CTCCCCCATCTCCGCCTGGGG-3′ for Family 1 and 5′-CCGGGGGCTCTGACCCGCCTGGGGA-GAA-3′ for Family 2) according to the manufacturer's specifications. After confirming that the desired mutation was present, a GH1 gene fragment containing the mutation was excised from the M13mp19/hGH clone by digestion with BglII and AvrII and ligated to the corresponding BglII/AvrII sites of the pXGH5 expression vector.
DNA transfections were carried out in HeLa cells using the Gibco calcium phosphate transfection system (Gibco-Bethesda Research Laboratories, Gaithersburg, MD). Cells were grown in 110 mm 2 dishes to 50% confluency and then transfected with 10 µg GH plasmid DNA per dish in accordance with the manufacturer's instructions. The cells were harvested 48 h after transfection, flash frozen and stored at -70_C (4).
Synthesis and amplification of GH complementary DNA (cDNA)
Messenger RNA was isolated from transfected cells and used as template for cDNA synthesis using RT-PCR (4). First strand cDNA synthesis was done using the Superscript pre-amplification system (Gibco-Bethesda Research Laboratories, Gaithersburg, MD) and a reverse primer corresponding to the complement of nt 6775-6753 (5′-ACAAGGCTGGTGGGCACTGGAGT-3′) of the GH gene cluster (9) . First strand cDNA products were then used as templates for PCR amplification under standard conditions. The forward and reverse primers corresponded to nt 5543-5565 (5′-GGCTTCAAGAGGGCAGTGCCTTC-3′) and the complement of 6775-6753. The PCR reaction mixture was denatured for 6 min at 94_C, cycled 55 times (94_C, 1 min; 69_C, 30 s; 72_C, 1 min), followed by a 10 min extension at 72_C. The resulting GH1 cDNA products were cleaned by filtration with a Microcon-100 microconcentrator, separated on an 8% polyacrylamide gel and the fragments sequenced (Fig. 2) as described above.
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